News

February 18, 2025

Cellphire Therapeutics Reaches Interim Analysis Milestone of 150 Patients in Phase 2/3 CRYPTICS Clinical Study

Cellphire Therapeutics has completed enrollment of 150 subjects in its CRYPTICS clinical trial, triggering an interim analysis to evaluate the safety and efficacy of its investigational cryopreserved platelet product, CLPH-511, for uncontrolled bleeding in cardiopulmonary bypass surgery. This milestone brings the company closer to offering a platelet alternative with extended shelf life, potentially improving access to critical care.

August 5, 2024

Cellphire Therapeutics announces the addition of Dr. Damien Bates as Chief Medical Officer and transition of Allan Alexander, our current CMO to an advisory role.

We are excited to announce that Damien Bates, MD, PhD, FRACS, MBA joined the company as Chief Medical Officer.

June 10, 2024

Completion of Phase 2 clinical trial of Thrombosomes® (FPH) in Acute Thoracic Aortic Dissections (TTAD)

Cellphire Therapeutics acknowledges Rigshospitalet Copenhagen University Hospital for completing enrollment ahead of schedule in their study of Thrombosomes® (FPH) for Acute Aortic Dissections, marking a significant advancement in life-saving cellular therapeutics. Dr. Jakob Stensballe and Dr. Annette Ulrich led the Copenhagen team's exceptional effort, demonstrating a shared commitment to innovation and patient care, with optimism for the potential impact of FPH technology on improving patient outcomes.

June 3, 2024

Cellphire Therapeutics announces the addition of Dr. Ed Coles to its Program Management and Executive Leadership teams.

We are excited to welcome Dr Edward Coles to the Cellphire management team!

May 13, 2024

Cellphire Therapeutics Forms Strategic Partnership with Vitalant, Bolstering Support for Freeze-Dried Platelet Derived Hemostat and Cryopreserved Platelets

Cellphire is excited to announce a strategic partnership with Vitalant, one of the nation’s largest nonprofit blood and biotherapies healthcare organizations. The partnership includes an initial investment by Vitalant and support for Cellphire's product development and clinical manufacturing processes of its freeze-dried platelet derived hemostat (FPH) and Cryopreserved Platelets.

April 24, 2024

Cellphire Therapeutics is nominated for Emerging Life Science Company of the Year by Maryland Tech Council!

The nomination underscores Cellphire's commitment to innovation and its contributions to the life sciences industry. With a focus on developing next-generation allogeneic cellular therapeutic technologies, Cellphire has emerged as a leader in the field, driving advancements that have the potential to revolutionize product availability.

April 23, 2024

Cellphire Therapeutics Issued New Core Technology Patent For Use of Stabilized Platelet Loaded With Anti-Cancer Agents

Cellphire Therapeutics was issued a patent, entitled Platelets Loaded with Anti-Cancer Agents (US Patent 11,965,178 B2 ('178 Patent) covering innovation in the use of Freeze-Dried Platelet-Derived Hemostat Technology (FPH) and/or FPH technology loaded with anti-cancer compounds for treating several cancers efficaciously while reducing toxicity.

September 26, 2023

Cellphire Therapeutics Issued New Core Technology Patent covering the use of Stabilized Platelets for Drug Delivery

Cellphire Therapeutics, Inc. was issued a patent entitled "Platelets as Delivery Agents" (US Patent 11,767,511, B2 ('511 Patent) covering innovation in the use of Freeze-Dried Platelet-Derived Hemostat Technology (FPH) for select drug delivery applications.